首页> 美国卫生研究院文献>Journal of Blood Medicine >Post-Transfusion Purpura: Current Perspectives
【2h】

Post-Transfusion Purpura: Current Perspectives

机译:输血后紫癜:当前观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Post transfusion purpura (PTP) is an uncommonly reported post transfusion adverse event that can present with severe thrombocytopenia; sometimes resulting in significant bleeding and hemorrhage. Its diagnosis can be elusive given its substantial symptomatic overlap with other thrombocytopenic syndromes. Underdiagnosis and underreporting make the true incidence of disease difficult to define. While clinical suspicion is key, laboratory evidence of platelet-targeted antibodies and identification of the antigen(s) they recognize are necessary to confirm the diagnosis. A curious aspect of PTP is paradoxical destruction of both transfused and autologous platelets. Although the first case was reported over 50 years ago, this aspect of PTP pathogenesis is still not fully understood and is widely debated. Several theories exist, but conclusive evidence to support most is lacking. Despite limited understanding of disease incidence and etiology, treatment with IVIG (Intravenous Immunoglobulin) has become standard practice and can be highly effective. Although recurrence is rare, precautions should be taken if patients with a history of PTP require transfusions in the future.
机译:输血后紫癜(PTP)是一种罕见的输血后不良事件,可伴有严重的血小板减少症。有时会导致严重的出血和出血。鉴于其与其他血小板减少综合征的实质性症状重叠,其诊断可能难以捉摸。诊断不足和报告不足使疾病的真实发生率难以确定。尽管临床怀疑是关键,但血小板靶向抗体的实验室证据以及它们识别的抗原的鉴定对于确认诊断是必要的。 PTP的一个有趣方面是输血和自体血小板的矛盾破坏。尽管第一例病例报道于50年前,但PTP发病机制的这一方面仍未完全了解,并引起了广泛的争论。存在几种理论,但是缺乏支持大多数理论的确凿证据。尽管对疾病的发生率和病因了解有限,但IVIG(静脉免疫球蛋白)治疗已成为标准做法,并且可能非常有效。尽管复发很少见,但是如果有PTP病史的患者将来需要输血,则应采取预防措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号